Form 4: MYGN CSO Sells Shares for Tax Obligations
Insider Transaction Report
Myriad Genetics Chief Scientific Officer Dale Muzzey disposed of 418 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
Summary
- Dale Muzzey, Chief Scientific Officer of Myriad Genetics Inc. (MYGN), reported a transaction on January 1, 2026.
- The transaction involved the disposition of 418 shares of Myriad Genetics common stock.
- These shares were withheld by the company to satisfy tax withholding obligations associated with the vesting of restricted stock units granted to Mr. Muzzey.
- The price per share for the disposition was $6.15, determined by the closing price of Myriad common stock on December 31, 2025.
- Following this transaction, Mr. Muzzey beneficially owns 170,181 shares of Myriad Genetics common stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary disposition of shares for tax purposes, which is a neutral event and does not reflect a change in the company's operational or financial performance.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This is a routine insider transaction related to compensation and tax obligations, which is common across all industries for executives receiving equity-based compensation. It does not provide specific insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in insider sentiment or company fundamentals.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Closing price of Myriad common stock used to determine the number of shares withheld for tax obligations. |
| 01/01/2026 | Date of transaction where shares were disposed of for tax withholding. |
| 01/02/2026 | Signature date of the reporting person for the Form 4 filing. |
Recommendation
holdThe filing details a routine tax-related disposition of shares by an insider, which does not reflect a change in the company's fundamentals or the insider's investment conviction. Therefore, it does not warrant a change in investment recommendation.
Keywords
MYRIAD GENETICS, MYGN, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Dale Muzzey, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.